Showing posts with label Clostridium difficile. Show all posts
Showing posts with label Clostridium difficile. Show all posts

Tuesday, November 06, 2012

Antibiotics: friend or foe?

Antibiotics: friend or foe?


Monday, November 05, 2012

By David Templeton, Pittsburgh Post-Gazette


When patients demand antibiotics for a cold, the flu, or any other viral infections, physicians sometimes appease them with a prescription. On other occasions, doctors prescribe antibiotics for infections most commonly caused by viruses but sometimes caused by bacteria or that progress to a bacterial infection.

Antibiotics kill germs -- bacteria -- and have no effect on viruses, making the above practices unnecessary and dangerous to health.

The overuse of antibiotics not only boosts health care costs but also causes bacterial resistance to the drugs. Examples include the growing difficulty in treating serious and sometimes fatal bacterial infections, methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C diff), both of which are on the rise.

Researchers also are linking health problems during childhood to early use and overuse of antibiotics.

When given in the first six months of life, antibiotics are now being suspected of leading to obesity and even type 2 diabetes, with a lifelong ripple effect on health. Antibiotics also can alter a child's immune system, although the health impacts are not yet clear.

"Antibiotic resistance is one of the world's most pressing public health threats," the U.S. Centers for Disease Control and Prevention states. More than 50 percent of antibiotics are unnecessarily prescribed in doctors' offices for upper respiratory infections including coughs and colds, most of which are caused by viruses. Half of all antibiotics used in hospitals are unnecessary or inappropriate, the CDC says.


Reactions that children have to antibiotics "are the most common cause of emergency department visits for adverse drug events," according to the CDC. Children can have as many as nine colds a year. Studies show that three of 10 children who receive outpatient health care for the common cold are prescribed unneeded antibiotics.

While those numbers have been improving in recent years, any unneeded use of antibiotics causes harm. For the past 70 years, antibiotics have been powerful tools, but their overuse is changing that. 

"Antibiotic resistance occurs when bacteria change in a way that reduces or eliminates the effectiveness of antibiotics," the CDC's "Get Smart" program states. "Infections with resistant bacteria have become more common in health care and community settings, and many bacteria have become resistant to more than one type or class of antibiotics."

It also is getting more difficult to develop new antibiotic drugs.

"The problem is that we expect antibiotics to work for every illness, but they don't," the CDC says, calling for more effective antibiotic stewardship programs.

Arjun Srinivasan, associate director of CDC's health-care-associated infection prevention programs, said the "Get Smart" programs are making progress in improving how antibiotics are used, but the problem is far from being resolved. Next week is CDC's "Get Smart" week to raise national awareness about the problem.

Recent research completed at New York University's Langone Medical Center has found that antibiotics prescribed for infants in the first six months of life can alter the baby's metabolism in ways that can lead to obesity and even type 2 diabetes, with the chance of those health impacts resonating throughout the person's life.

Studies completed under the leadership of Martin Blaser, chairman of the medical center's department of medicine, determined that early doses of antibiotics kill off the natural flora in the gut, or the good bacteria that are  not only necessary to defend against bacterial infections but also involved in metabolism.

Early doses of antibiotics intensify the metabolism, causing extraction of more calories than normal from food, leading to weight gain. Dr. Blaser said a 15-year-long epidemiological study in England found that children treated with antibiotics in the first months of life had a 22 percent higher rate of obesity than those who didn't receive antibiotics during that time period. The findings, he said, may help explain the rise in type 2 diabetes in children.

A mouse study, done earlier by the team, reached similar conclusions about antibiotics altering the metabolism and immune system, he said. But evidence long has existed that antibiotics cause weight gain.

"One of the things that pointed me in this direction was the knowledge over the last 60 years that farmers were giving low doses of antibiotics to livestock to fatten them up," Dr. Blaser said. "Antibiotics are growth promoters, and they established the principles that antibiotics early in life affect early development."

The research also documented changes induced by antibiotics in different T-cell populations in the immune system.

"We are changing the composition of the natural flora and the change in composition is happening at a critical time in the child's development," Dr. Blaser said. "What happens in early life sets the stage for overall development for the rest of the person's life."

He's now working to identify how changes in the natural flora, or "microbiota," cause changes to metabolism and the immune system with hope of developing a probiotic treatment to restore the natural flora to counter or reduce the health impacts of antibiotics.

Dr. Srinivasan praised Dr. Blaser's research that identifies other health concerns linked to the use of antibiotics. But the focus is on bacterial resistance.

"Certainly the situation with antibiotic resistance is getting worse," he said. "Bacteria are developing resistance to more antibiotics, making it more difficult to treat patients or to find the right treatments for the right patients."
The overuse of antibiotics isn't limited by age group.

A University of Pittsburgh-based research team, using Medicare Part D data from 2007 to 2009, found that one in five people 65 and older are taking at last one course of antibiotic during any three-month season of the year, with 47 percent taking at least one dose of antibiotics sometime during the year.

The study was published Sept. 24 online in the Journal of the American Medical Association's Archives of Internal Medicine.

Doctors who treat older adults in Southern states prescribe antibiotics more often than any other region in the United States, the study says. On average, 21.4 percent of older adults in the South are taking antibiotics during any three-month period of the year. Western states have the lowest seasonal rate of 17.4 percent, with the Northeast at 18.2 percent and the Midwest at 19.2 percent. The usage rate is highest January through March, and lowest from July through September.

The study found variations in antibiotic use across the regions, even after researchers adjusted for differences in population, suggesting that physicians and health care systems differ region to region in how antibiotics are prescribed.

Oregon and Wyoming had the lowest rate of antibiotic use among seniors, while Alabama and Mississippi had the highest. Pennsylvania ranked 23rd with 46 percent of older adults taking a course of antibiotics at least once during the year.

"Some conditions require antibiotics and some don't justify the use of antibiotics," said Yuting Zhang, the study author and assistant professor at Pitt's department of health policy and management. "Some regions do really well. What can we learn from them? What programs are they using? Can programs they are using in the West be adapted to the South?"

post-gasette



Sunday, March 23, 2008

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

Cochrane Database Syst Rev. 2007 Jul

Nelson R.
Northern General Hospital, Department of General Surgery, Herries Road, Sheffield, Yorkshire, UK, S5 7AU.
altohorn@btinternet.com

BACKGROUND: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhea and colitis.

OBJECTIVES: The aim of this review is to establish the efficacy of antibiotic therapy for C. difficile-associated diarrhea (CDAD), to identify the most effective antibiotic treatment for CDAD in adults and to determine the need for stopping the causative antibiotic during therapy.

SEARCH STRATEGY: MEDLINE (1966 to 2006), EMBASE (1980 to 2006), Cochrane Central Database of Controlled Trials and the Cochrane IBD Review Group Specialized Trials Register were searched using the following search terms: "pseudomembranous colitis and randomized trial"; "Clostridium difficile and randomized trial"; "antibiotic associated diarrhea and randomized trial".

SELECTION CRITERIA: Only randomized, controlled trials assessing antibiotic treatment for CDAD were included in the review. Probiotic trials are excluded. The following outcomes were sought: initial resolution of diarrhea; initial conversion of stool to C. difficile cytotoxin and/or stool culture negative; recurrence of diarrhea; recurrence of fecal C. difficile cytotoxin and/or positive stool culture; patient response to cessation of prior antibiotic therapy; sepsis; emergent surgery: fecal diversion or colectomy; and death.

DATA COLLECTION AND ANALYSIS: Data were analyzed using the MetaView statistical package in Review Manager. For dichotomous outcomes, relative risks (RR) and 95% confidence intervals (CI) were derived from each study. When appropriate, the results of included studies were combined for each outcome. For dichotomous outcomes, pooled RR and 95% CI were calculated using a fixed effect model, except where significant heterogeneity was detected, at which time the random effects model was used. Data heterogeneity was calculated using MetaView.

MAIN RESULTS: Twelve studies (total of 1157 participants) involving patients with diarrhea who recently received antibiotics for an infection other than C. difficile were included. The definition of diarrhea ranged from at least two loose stools per day with an associated symptom such as rectal temperature > 38 (o)C, to at least six loose stools in 36 hours. Eight different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin and bacitracin. In paired comparisons, no single antibiotic was clearly superior to others, though teicoplanin, an antibiotic of limited availability and great cost, showed in some outcomes significant benefit over vancomycin and fusidic acid, and a trend towards benefit compared to metronidazole. Only one placebo controlled trial was done and no conclusions can be drawn from it due to small size and classification error. Only one study investigated synergistic antibiotic combination, metronidazole and rifampin, and there was no advantage to the drug combination.

AUTHORS' CONCLUSIONS: Current evidence leads to uncertainty whether mild CDAD needs to be treated. Patients with mild CDAD may resolve their symptoms as quickly without treatment. The only placebo-controlled study shows vancomycin's superior efficacy. However, this result should be treated with caution due to the small number of patients enrolled and the poor methodological quality of the trial. The Johnson study of asymptomatic carriers also shows that placebo is better than vancomycin or metronidazole for eliminating C. difficile in stool during follow-up. If one does decide to treat, then two goals of therapy need to be kept in mind: improvement of the patient's clinical condition and prevention of spread of C. difficile infection to other patients. Given these two considerations, one should choose the antibiotic that brings both symptomatic cure and bacteriologic cure.

In this regard, teicoplanin appears to be the best choice because the available evidence suggests that it is better than vancomycin for bacteriologic cure and has borderline superior effectiveness in terms of symptomatic cure. Teicoplanin is not readily available in the United States, which must be taken into account when making treatment decisions in that country.

Plain language summary

Antibiotic therapy for Clostridium difficile-associated diarrhea (CDAD) needs further investigation.Diarrhea may be a side effect of many commonly used antibiotics, and this is in some cases due to overgrowth of a bacterium called Clostridium difficile (C. difficile) in the colon after other bacteria have been killed. The seriousness of C. difficile-associated diarrhea can range from being a nuisance to a life threatening or even fatal disease. The treatment of CDAD is usually cessation of the initiating antibiotic and immediate administration of a new antibiotic. However each of these three strategies, cessation of the original antibiotic, immediate retreatment, and the choice of a new antibiotic are poorly supported by currently available evidence. The antibiotic that is most tested, vancomycin, is the one most prone to serious side effects. Seven other antibiotics are included in this review and within the limitations of the included studies, they each seem to be as effective as vancomycin.

The Cochrane Library